Exploratory behavior models of anxiety in mice

Research output: Contribution to journalArticle

494 Citations (Scopus)

Abstract

Parameters of exploratory behaviors responsive to anti-anxiety drugs are reviewed with respect to their sensitivity and specificity for anxiolytics in mice. Mouse models appear to rest on a disinhibition of natural exploratory tendencies by anxiolytic treatments. Analysis of agonists of the brain benzodiazepine binding site, such as chlordiazepoxide and diazepam, significantly increase exploration of a hole-board, of a two-chambered light dark apparatus, increase social interaction under high levels of illumination, increase consumption of a novel food in an unfamiliar environment, and increase punished crossings in a footshock conflict paradigm. These tests detect anxiolytic responses at doses of benzodiazepines well within the clinically effective range. Pharmacological specificity was established for the hole-board and light dark transition tests, showing that non-anxiolytic categories of psychoactive drugs did not produce false positives. Open field behaviors and isolation-induced aggression were reduced by anxiolytics, at doses which may be within the sedative-hypnotic range. Analysis of antagonists of the brain benzodiazepine binding site did not show active antagonist properties in the light dark transitions model, although the antagonist Ro-15-1788 appeared to have partial agonist properties in the open field test, suggesting that rat models may be more sensitive to anxiogenic compounds than are mouse models. The wide separation between anxiolytic and sedative doses in mouse models recommend these exploration paradigms as good predictive screens for the testing of novel anxiolytic compounds.

Original languageEnglish (US)
Pages (from-to)37-44
Number of pages8
JournalNeuroscience and Biobehavioral Reviews
Volume9
Issue number1
DOIs
StatePublished - 1985
Externally publishedYes

Fingerprint

Exploratory Behavior
Anti-Anxiety Agents
Anxiety
Benzodiazepines
Hypnotics and Sedatives
Light
Binding Sites
Chlordiazepoxide
Flumazenil
Psychotropic Drugs
Brain
Interpersonal Relations
Diazepam
Lighting
Aggression
Pharmacology
Sensitivity and Specificity
Food

Keywords

  • Anxiety
  • Anxiolytics
  • Behavior models
  • Open field

ASJC Scopus subject areas

  • Behavioral Neuroscience

Cite this

Exploratory behavior models of anxiety in mice. / Crawley, Jacqueline.

In: Neuroscience and Biobehavioral Reviews, Vol. 9, No. 1, 1985, p. 37-44.

Research output: Contribution to journalArticle

@article{13384b1ef8a546e7af18bf3782073666,
title = "Exploratory behavior models of anxiety in mice",
abstract = "Parameters of exploratory behaviors responsive to anti-anxiety drugs are reviewed with respect to their sensitivity and specificity for anxiolytics in mice. Mouse models appear to rest on a disinhibition of natural exploratory tendencies by anxiolytic treatments. Analysis of agonists of the brain benzodiazepine binding site, such as chlordiazepoxide and diazepam, significantly increase exploration of a hole-board, of a two-chambered light dark apparatus, increase social interaction under high levels of illumination, increase consumption of a novel food in an unfamiliar environment, and increase punished crossings in a footshock conflict paradigm. These tests detect anxiolytic responses at doses of benzodiazepines well within the clinically effective range. Pharmacological specificity was established for the hole-board and light dark transition tests, showing that non-anxiolytic categories of psychoactive drugs did not produce false positives. Open field behaviors and isolation-induced aggression were reduced by anxiolytics, at doses which may be within the sedative-hypnotic range. Analysis of antagonists of the brain benzodiazepine binding site did not show active antagonist properties in the light dark transitions model, although the antagonist Ro-15-1788 appeared to have partial agonist properties in the open field test, suggesting that rat models may be more sensitive to anxiogenic compounds than are mouse models. The wide separation between anxiolytic and sedative doses in mouse models recommend these exploration paradigms as good predictive screens for the testing of novel anxiolytic compounds.",
keywords = "Anxiety, Anxiolytics, Behavior models, Open field",
author = "Jacqueline Crawley",
year = "1985",
doi = "10.1016/0149-7634(85)90030-2",
language = "English (US)",
volume = "9",
pages = "37--44",
journal = "Neuroscience and Biobehavioral Reviews",
issn = "0149-7634",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Exploratory behavior models of anxiety in mice

AU - Crawley, Jacqueline

PY - 1985

Y1 - 1985

N2 - Parameters of exploratory behaviors responsive to anti-anxiety drugs are reviewed with respect to their sensitivity and specificity for anxiolytics in mice. Mouse models appear to rest on a disinhibition of natural exploratory tendencies by anxiolytic treatments. Analysis of agonists of the brain benzodiazepine binding site, such as chlordiazepoxide and diazepam, significantly increase exploration of a hole-board, of a two-chambered light dark apparatus, increase social interaction under high levels of illumination, increase consumption of a novel food in an unfamiliar environment, and increase punished crossings in a footshock conflict paradigm. These tests detect anxiolytic responses at doses of benzodiazepines well within the clinically effective range. Pharmacological specificity was established for the hole-board and light dark transition tests, showing that non-anxiolytic categories of psychoactive drugs did not produce false positives. Open field behaviors and isolation-induced aggression were reduced by anxiolytics, at doses which may be within the sedative-hypnotic range. Analysis of antagonists of the brain benzodiazepine binding site did not show active antagonist properties in the light dark transitions model, although the antagonist Ro-15-1788 appeared to have partial agonist properties in the open field test, suggesting that rat models may be more sensitive to anxiogenic compounds than are mouse models. The wide separation between anxiolytic and sedative doses in mouse models recommend these exploration paradigms as good predictive screens for the testing of novel anxiolytic compounds.

AB - Parameters of exploratory behaviors responsive to anti-anxiety drugs are reviewed with respect to their sensitivity and specificity for anxiolytics in mice. Mouse models appear to rest on a disinhibition of natural exploratory tendencies by anxiolytic treatments. Analysis of agonists of the brain benzodiazepine binding site, such as chlordiazepoxide and diazepam, significantly increase exploration of a hole-board, of a two-chambered light dark apparatus, increase social interaction under high levels of illumination, increase consumption of a novel food in an unfamiliar environment, and increase punished crossings in a footshock conflict paradigm. These tests detect anxiolytic responses at doses of benzodiazepines well within the clinically effective range. Pharmacological specificity was established for the hole-board and light dark transition tests, showing that non-anxiolytic categories of psychoactive drugs did not produce false positives. Open field behaviors and isolation-induced aggression were reduced by anxiolytics, at doses which may be within the sedative-hypnotic range. Analysis of antagonists of the brain benzodiazepine binding site did not show active antagonist properties in the light dark transitions model, although the antagonist Ro-15-1788 appeared to have partial agonist properties in the open field test, suggesting that rat models may be more sensitive to anxiogenic compounds than are mouse models. The wide separation between anxiolytic and sedative doses in mouse models recommend these exploration paradigms as good predictive screens for the testing of novel anxiolytic compounds.

KW - Anxiety

KW - Anxiolytics

KW - Behavior models

KW - Open field

UR - http://www.scopus.com/inward/record.url?scp=0021972205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021972205&partnerID=8YFLogxK

U2 - 10.1016/0149-7634(85)90030-2

DO - 10.1016/0149-7634(85)90030-2

M3 - Article

C2 - 2858080

AN - SCOPUS:0021972205

VL - 9

SP - 37

EP - 44

JO - Neuroscience and Biobehavioral Reviews

JF - Neuroscience and Biobehavioral Reviews

SN - 0149-7634

IS - 1

ER -